Overview
On 15 May 2009, orphan designation (EU/3/09/637) was granted by the European Commission to Wellstat Therapeutics EU Limited, United Kingdom, for 2',3',5'-tri-O-acetyluridine for the treatment of 5-fluorouracil overdose.
The sponsorship was transferred to Wellstat Therapeutics EU Limited, Ireland, in February 2021.
Key facts
Active substance |
2',3',5'-Tri-O-acetyluridine
|
Intended use |
Treatment of 5-fluorouracil overdose
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/09/637
|
Date of designation |
15/05/2009
|
Sponsor |
Wellstat Therapeutics EU Limited |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: